Dronabinol in severe, enduring anorexia nervosa: A randomized controlled trial
ABSTRACT Objective The evidence for pharmacological treatment of severe, longstanding anorexia nervosa (AN) is sparse and the few controlled pharmacologic studies have focused on a narrow range of drugs. The aim of the present study was to investigate the effects of treatment with a synthetic cannab...
Gespeichert in:
| Veröffentlicht in: | The International journal of eating disorders 2014-01, Vol.47 (1), p.18-23 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 23 |
|---|---|
| container_issue | 1 |
| container_start_page | 18 |
| container_title | The International journal of eating disorders |
| container_volume | 47 |
| creator | Andries, Alin Frystyk, Jan Flyvbjerg, Allan Støving, René Klinkby |
| description | ABSTRACT
Objective
The evidence for pharmacological treatment of severe, longstanding anorexia nervosa (AN) is sparse and the few controlled pharmacologic studies have focused on a narrow range of drugs. The aim of the present study was to investigate the effects of treatment with a synthetic cannabinoid agonist on body weight and eating disorder‐related psychopathological personality traits in women with severe, enduring AN.
Method
This add‐on, prospective, randomized, double blind, controlled crossover study was conducted between 2008 and 2011 at a specialized care center for eating disorders. Twenty‐five women over 18 years with AN of at least 5 years duration were randomized to treatment with either dronabinol‐placebo or placebo‐dronabinol. In addition to the standardized baseline therapeutic regime, the participants received dronabinol, 2.5 mg twice daily for 4 weeks and matching placebo for 4 weeks, separated by a 4‐week wash‐out period. Primary outcome was the mean change in body weight. Secondary outcome was score changes on the Eating Disorder Inventory‐2 (EDI‐2). Data were analyzed for the 24 patients who completed the trial.
Results
During dronabinol treatment, participants gained 0.73 kg (t = 2.86, df = 22, p |
| doi_str_mv | 10.1002/eat.22173 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1467065310</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3162867851</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3913-f82d2c539b0dd31e090dbfa0b7e6d0919d60dcda40bc038266bcb88e039e4613</originalsourceid><addsrcrecordid>eNp10E1LxDAQBuAgiq4fB_-AFLwoWJ0kbdJ6W9RdBdGDC3oLaTMr0W6iSbt-_Hqrqx4ETzOHZ16Gl5BtCocUgB2hbg8Zo5IvkQGFskgpFHfLZABMipRnslgj6zE-AIDgkK-SNZZRyAWFAbk6Dd7pyjrfJNYlEecY8CBBZ7pg3X2inQ_4anXiMMx91MfJMAnaGT-z72iS2rs2-Kbp1zZY3WySlaluIm59zw0yGZ1NTs7Ty-vxxcnwMq15SXk6LZhhdc7LCozhFKEEU001VBKFgZKWRoCpjc6gqoEXTIiqrooCgZeYCco3yN4i9in45w5jq2Y21tg02qHvoqKZkCByTqGnu3_og--C65_rlQQoRJazXu0vVB18jAGn6inYmQ5vioL67Fj1Hauvjnu7853YVTM0v_Kn1B4cLcCLbfDt_yR1Npz8RKaLCxtbfP290OFRCcllrm6vxur8Ro5GQKka8w-rzZO2</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1470086452</pqid></control><display><type>article</type><title>Dronabinol in severe, enduring anorexia nervosa: A randomized controlled trial</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Andries, Alin ; Frystyk, Jan ; Flyvbjerg, Allan ; Støving, René Klinkby</creator><creatorcontrib>Andries, Alin ; Frystyk, Jan ; Flyvbjerg, Allan ; Støving, René Klinkby</creatorcontrib><description>ABSTRACT
Objective
The evidence for pharmacological treatment of severe, longstanding anorexia nervosa (AN) is sparse and the few controlled pharmacologic studies have focused on a narrow range of drugs. The aim of the present study was to investigate the effects of treatment with a synthetic cannabinoid agonist on body weight and eating disorder‐related psychopathological personality traits in women with severe, enduring AN.
Method
This add‐on, prospective, randomized, double blind, controlled crossover study was conducted between 2008 and 2011 at a specialized care center for eating disorders. Twenty‐five women over 18 years with AN of at least 5 years duration were randomized to treatment with either dronabinol‐placebo or placebo‐dronabinol. In addition to the standardized baseline therapeutic regime, the participants received dronabinol, 2.5 mg twice daily for 4 weeks and matching placebo for 4 weeks, separated by a 4‐week wash‐out period. Primary outcome was the mean change in body weight. Secondary outcome was score changes on the Eating Disorder Inventory‐2 (EDI‐2). Data were analyzed for the 24 patients who completed the trial.
Results
During dronabinol treatment, participants gained 0.73 kg (t = 2.86, df = 22, p < 0.01) above placebo without significant psychotropic adverse events. Dronabinol significantly predicted weight gain in a multiple linear regression including EDI‐2 body dissatisfaction score and leptin. EDI‐2 subscale scores showed no significant changes over time.
Discussion
Dronabinol therapy was well tolerated. During four weeks of exposure it induced a small but significant weight gain in the absence of severe adverse events. © 2013 Wiley Periodicals, Inc. (Int J Eat Disord 2014; 47:18–23)</description><identifier>ISSN: 0276-3478</identifier><identifier>EISSN: 1098-108X</identifier><identifier>DOI: 10.1002/eat.22173</identifier><identifier>PMID: 24105610</identifier><identifier>CODEN: INDIDJ</identifier><language>eng</language><publisher>United States: Blackwell Publishing Ltd</publisher><subject>Adult ; Anorexia ; anorexia nervosa ; Anorexia Nervosa - drug therapy ; Anorexia Nervosa - etiology ; Anorexia Nervosa - rehabilitation ; Body Weight - drug effects ; cannabinoid ; Cannabinoid Receptor Agonists - adverse effects ; Cannabinoid Receptor Agonists - therapeutic use ; Clinical trials ; Cross-Over Studies ; Denmark ; Double-Blind Method ; dronabinol ; Dronabinol - adverse effects ; Dronabinol - therapeutic use ; Drug therapy ; eating disorder inventory ; Eating disorders ; Female ; Humans ; leptin ; Middle Aged ; Nutritional Support ; Personality traits ; Pharmacology ; Prospective Studies ; Psychopathology ; Treatment Outcome ; weight ; Weight Gain ; Womens health</subject><ispartof>The International journal of eating disorders, 2014-01, Vol.47 (1), p.18-23</ispartof><rights>Copyright © 2013 Wiley Periodicals, Inc.</rights><rights>Copyright Wiley Periodicals Inc. Jan 2014</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3913-f82d2c539b0dd31e090dbfa0b7e6d0919d60dcda40bc038266bcb88e039e4613</citedby><cites>FETCH-LOGICAL-c3913-f82d2c539b0dd31e090dbfa0b7e6d0919d60dcda40bc038266bcb88e039e4613</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Feat.22173$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Feat.22173$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1416,27915,27916,45565,45566</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24105610$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Andries, Alin</creatorcontrib><creatorcontrib>Frystyk, Jan</creatorcontrib><creatorcontrib>Flyvbjerg, Allan</creatorcontrib><creatorcontrib>Støving, René Klinkby</creatorcontrib><title>Dronabinol in severe, enduring anorexia nervosa: A randomized controlled trial</title><title>The International journal of eating disorders</title><addtitle>Int. J. Eat. Disord</addtitle><description>ABSTRACT
Objective
The evidence for pharmacological treatment of severe, longstanding anorexia nervosa (AN) is sparse and the few controlled pharmacologic studies have focused on a narrow range of drugs. The aim of the present study was to investigate the effects of treatment with a synthetic cannabinoid agonist on body weight and eating disorder‐related psychopathological personality traits in women with severe, enduring AN.
Method
This add‐on, prospective, randomized, double blind, controlled crossover study was conducted between 2008 and 2011 at a specialized care center for eating disorders. Twenty‐five women over 18 years with AN of at least 5 years duration were randomized to treatment with either dronabinol‐placebo or placebo‐dronabinol. In addition to the standardized baseline therapeutic regime, the participants received dronabinol, 2.5 mg twice daily for 4 weeks and matching placebo for 4 weeks, separated by a 4‐week wash‐out period. Primary outcome was the mean change in body weight. Secondary outcome was score changes on the Eating Disorder Inventory‐2 (EDI‐2). Data were analyzed for the 24 patients who completed the trial.
Results
During dronabinol treatment, participants gained 0.73 kg (t = 2.86, df = 22, p < 0.01) above placebo without significant psychotropic adverse events. Dronabinol significantly predicted weight gain in a multiple linear regression including EDI‐2 body dissatisfaction score and leptin. EDI‐2 subscale scores showed no significant changes over time.
Discussion
Dronabinol therapy was well tolerated. During four weeks of exposure it induced a small but significant weight gain in the absence of severe adverse events. © 2013 Wiley Periodicals, Inc. (Int J Eat Disord 2014; 47:18–23)</description><subject>Adult</subject><subject>Anorexia</subject><subject>anorexia nervosa</subject><subject>Anorexia Nervosa - drug therapy</subject><subject>Anorexia Nervosa - etiology</subject><subject>Anorexia Nervosa - rehabilitation</subject><subject>Body Weight - drug effects</subject><subject>cannabinoid</subject><subject>Cannabinoid Receptor Agonists - adverse effects</subject><subject>Cannabinoid Receptor Agonists - therapeutic use</subject><subject>Clinical trials</subject><subject>Cross-Over Studies</subject><subject>Denmark</subject><subject>Double-Blind Method</subject><subject>dronabinol</subject><subject>Dronabinol - adverse effects</subject><subject>Dronabinol - therapeutic use</subject><subject>Drug therapy</subject><subject>eating disorder inventory</subject><subject>Eating disorders</subject><subject>Female</subject><subject>Humans</subject><subject>leptin</subject><subject>Middle Aged</subject><subject>Nutritional Support</subject><subject>Personality traits</subject><subject>Pharmacology</subject><subject>Prospective Studies</subject><subject>Psychopathology</subject><subject>Treatment Outcome</subject><subject>weight</subject><subject>Weight Gain</subject><subject>Womens health</subject><issn>0276-3478</issn><issn>1098-108X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp10E1LxDAQBuAgiq4fB_-AFLwoWJ0kbdJ6W9RdBdGDC3oLaTMr0W6iSbt-_Hqrqx4ETzOHZ16Gl5BtCocUgB2hbg8Zo5IvkQGFskgpFHfLZABMipRnslgj6zE-AIDgkK-SNZZRyAWFAbk6Dd7pyjrfJNYlEecY8CBBZ7pg3X2inQ_4anXiMMx91MfJMAnaGT-z72iS2rs2-Kbp1zZY3WySlaluIm59zw0yGZ1NTs7Ty-vxxcnwMq15SXk6LZhhdc7LCozhFKEEU001VBKFgZKWRoCpjc6gqoEXTIiqrooCgZeYCco3yN4i9in45w5jq2Y21tg02qHvoqKZkCByTqGnu3_og--C65_rlQQoRJazXu0vVB18jAGn6inYmQ5vioL67Fj1Hauvjnu7853YVTM0v_Kn1B4cLcCLbfDt_yR1Npz8RKaLCxtbfP290OFRCcllrm6vxur8Ro5GQKka8w-rzZO2</recordid><startdate>201401</startdate><enddate>201401</enddate><creator>Andries, Alin</creator><creator>Frystyk, Jan</creator><creator>Flyvbjerg, Allan</creator><creator>Støving, René Klinkby</creator><general>Blackwell Publishing Ltd</general><general>Wiley Subscription Services, Inc</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TS</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>201401</creationdate><title>Dronabinol in severe, enduring anorexia nervosa: A randomized controlled trial</title><author>Andries, Alin ; Frystyk, Jan ; Flyvbjerg, Allan ; Støving, René Klinkby</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3913-f82d2c539b0dd31e090dbfa0b7e6d0919d60dcda40bc038266bcb88e039e4613</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adult</topic><topic>Anorexia</topic><topic>anorexia nervosa</topic><topic>Anorexia Nervosa - drug therapy</topic><topic>Anorexia Nervosa - etiology</topic><topic>Anorexia Nervosa - rehabilitation</topic><topic>Body Weight - drug effects</topic><topic>cannabinoid</topic><topic>Cannabinoid Receptor Agonists - adverse effects</topic><topic>Cannabinoid Receptor Agonists - therapeutic use</topic><topic>Clinical trials</topic><topic>Cross-Over Studies</topic><topic>Denmark</topic><topic>Double-Blind Method</topic><topic>dronabinol</topic><topic>Dronabinol - adverse effects</topic><topic>Dronabinol - therapeutic use</topic><topic>Drug therapy</topic><topic>eating disorder inventory</topic><topic>Eating disorders</topic><topic>Female</topic><topic>Humans</topic><topic>leptin</topic><topic>Middle Aged</topic><topic>Nutritional Support</topic><topic>Personality traits</topic><topic>Pharmacology</topic><topic>Prospective Studies</topic><topic>Psychopathology</topic><topic>Treatment Outcome</topic><topic>weight</topic><topic>Weight Gain</topic><topic>Womens health</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Andries, Alin</creatorcontrib><creatorcontrib>Frystyk, Jan</creatorcontrib><creatorcontrib>Flyvbjerg, Allan</creatorcontrib><creatorcontrib>Støving, René Klinkby</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Physical Education Index</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>The International journal of eating disorders</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Andries, Alin</au><au>Frystyk, Jan</au><au>Flyvbjerg, Allan</au><au>Støving, René Klinkby</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dronabinol in severe, enduring anorexia nervosa: A randomized controlled trial</atitle><jtitle>The International journal of eating disorders</jtitle><addtitle>Int. J. Eat. Disord</addtitle><date>2014-01</date><risdate>2014</risdate><volume>47</volume><issue>1</issue><spage>18</spage><epage>23</epage><pages>18-23</pages><issn>0276-3478</issn><eissn>1098-108X</eissn><coden>INDIDJ</coden><abstract>ABSTRACT
Objective
The evidence for pharmacological treatment of severe, longstanding anorexia nervosa (AN) is sparse and the few controlled pharmacologic studies have focused on a narrow range of drugs. The aim of the present study was to investigate the effects of treatment with a synthetic cannabinoid agonist on body weight and eating disorder‐related psychopathological personality traits in women with severe, enduring AN.
Method
This add‐on, prospective, randomized, double blind, controlled crossover study was conducted between 2008 and 2011 at a specialized care center for eating disorders. Twenty‐five women over 18 years with AN of at least 5 years duration were randomized to treatment with either dronabinol‐placebo or placebo‐dronabinol. In addition to the standardized baseline therapeutic regime, the participants received dronabinol, 2.5 mg twice daily for 4 weeks and matching placebo for 4 weeks, separated by a 4‐week wash‐out period. Primary outcome was the mean change in body weight. Secondary outcome was score changes on the Eating Disorder Inventory‐2 (EDI‐2). Data were analyzed for the 24 patients who completed the trial.
Results
During dronabinol treatment, participants gained 0.73 kg (t = 2.86, df = 22, p < 0.01) above placebo without significant psychotropic adverse events. Dronabinol significantly predicted weight gain in a multiple linear regression including EDI‐2 body dissatisfaction score and leptin. EDI‐2 subscale scores showed no significant changes over time.
Discussion
Dronabinol therapy was well tolerated. During four weeks of exposure it induced a small but significant weight gain in the absence of severe adverse events. © 2013 Wiley Periodicals, Inc. (Int J Eat Disord 2014; 47:18–23)</abstract><cop>United States</cop><pub>Blackwell Publishing Ltd</pub><pmid>24105610</pmid><doi>10.1002/eat.22173</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0276-3478 |
| ispartof | The International journal of eating disorders, 2014-01, Vol.47 (1), p.18-23 |
| issn | 0276-3478 1098-108X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1467065310 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Adult Anorexia anorexia nervosa Anorexia Nervosa - drug therapy Anorexia Nervosa - etiology Anorexia Nervosa - rehabilitation Body Weight - drug effects cannabinoid Cannabinoid Receptor Agonists - adverse effects Cannabinoid Receptor Agonists - therapeutic use Clinical trials Cross-Over Studies Denmark Double-Blind Method dronabinol Dronabinol - adverse effects Dronabinol - therapeutic use Drug therapy eating disorder inventory Eating disorders Female Humans leptin Middle Aged Nutritional Support Personality traits Pharmacology Prospective Studies Psychopathology Treatment Outcome weight Weight Gain Womens health |
| title | Dronabinol in severe, enduring anorexia nervosa: A randomized controlled trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T05%3A57%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dronabinol%20in%20severe,%20enduring%20anorexia%20nervosa:%20A%20randomized%20controlled%20trial&rft.jtitle=The%20International%20journal%20of%20eating%20disorders&rft.au=Andries,%20Alin&rft.date=2014-01&rft.volume=47&rft.issue=1&rft.spage=18&rft.epage=23&rft.pages=18-23&rft.issn=0276-3478&rft.eissn=1098-108X&rft.coden=INDIDJ&rft_id=info:doi/10.1002/eat.22173&rft_dat=%3Cproquest_cross%3E3162867851%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1470086452&rft_id=info:pmid/24105610&rfr_iscdi=true |